+515.5%
AEHR vs GSK
+331.0%
+184.5%
-98.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +5.3% | -2.7% | +8.0% | +5.9% |
| 7D | +18.5% | -4.2% | +22.7% | +19.6% |
| 30D | -11.9% | -7.5% | -4.4% | -10.7% |
| 3M | -5.0% | -3.3% | -1.7% | -5.2% |
| 6M | +155.0% | -9.3% | +164.3% | +159.3% |
| YTD | +349.7% | +1.6% | +348.1% | +342.3% |
| 1Y | +260.4% | +25.5% | +234.9% | +236.7% |
| 3Y | +83.6% | +49.3% | +34.3% | +62.0% |
| 5Y | +917.8% | +46.7% | +871.2% | +788.5% |
| 10Y | +3,517.1% | +76.8% | +3,440.3% | +2,871.8% |
| All | +515.5% | +331.0% | +184.5% | +329.5% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling